Show simple item record

dc.contributor.authorLi, A.Y.
dc.contributor.authorKashanian, S.M.
dc.contributor.authorHambley, B.C.
dc.contributor.authorZacholski, K.
dc.contributor.authorDuong, V.H.
dc.contributor.authorChaer, F.E.
dc.contributor.authorHoltzman, N.G.
dc.contributor.authorGojo, I.
dc.contributor.authorWebster, J.A.
dc.contributor.authorNorsworthy, K.J.
dc.contributor.authorSmith, B.D.
dc.contributor.authorDezern, A.E.
dc.contributor.authorLevis, M.J.
dc.contributor.authorBaer, M.R.
dc.contributor.authorKamangar, F.
dc.contributor.authorGhiaur, G.
dc.contributor.authorEmadi, A.
dc.date.accessioned2021-04-12T13:11:08Z
dc.date.available2021-04-12T13:11:08Z
dc.date.issued2021-03-21
dc.identifier.urihttp://hdl.handle.net/10713/15151
dc.description.abstractThe significance of FLT3-ITD in acute promyelocytic leukemia (APL) is not well-established. We performed a bi-center retrospective study of 138 APL patients, 59 (42.8%) of whom had FLT3-ITD. APL patients with FLT3-ITD had higher baseline white blood cell counts (WBCs) (p < 0.001), higher hemoglobin, (p = 0.03), higher aspartate aminotransferase (p = 0.001), lower platelets (p = 0.004), lower fibrinogen (p = 0.003), and higher incidences of disseminated intravascular coagulation (p = 0.005), M3v variant morphology (p < 0.001), and the bcr3 isoform (p < 0.001). FLT3-ITD was associated with inferior post-consolidation complete remission (CR) (p = 0.02) and 5-year overall survival (OS) of 79.7%, compared to 94.4% for FLT3-WT (wild-type) (p = 0.02). FLT3-ITD was strongly associated with baseline WBCs ≥ 25 × 109/L (odds ratio (OR): 54.4; 95% CI: 10.4–286.1; p < 0.001). High FLT3-ITD allelic burdens correlated with high-risk (HR) Sanz scores and high WBCs, with every 1% increase in allelic burden corresponding to a 0.6 × 109/L increase in WBC. HR APL was associated with a 38.5% increase in allelic burden compared with low-risk (LR) APL (95% CI: 19.8–57.2; p < 0.001). Our results provide additional evidence that FLT3-ITD APL is a distinct subtype of APL that warrants further study to delineate potential differences in therapeutic approach. © 2021 by the authors.en_US
dc.description.sponsorshipThis research was partially funded by the University of Maryland Greenebaum Comprehensive Cancer Center Support Grant, grant number P30CA134274; the NHLBI, grant numbers K08HL127269 and R03HL145226; the NCI, grant number P01CA225618; and the State of Maryland's Cigarette Restitution Funds.en_US
dc.description.urihttps://doi.org/10.3390/biology10030243en_US
dc.language.isoen_USen_US
dc.publisherMDPI AGen_US
dc.relation.ispartofBiology
dc.subjectAPLen_US
dc.subjectFLT3-ITDen_US
dc.subjectLeukemiaen_US
dc.titleFlt3-itd allelic burden and acute promyelocytic leukemia risk stratificationen_US
dc.typeArticleen_US
dc.identifier.doi10.3390/biology10030243


This item appears in the following Collection(s)

Show simple item record